In a bid to remodel the controversial relationship between drugmakers and affected person charities, Regeneron Prescription drugs has introduced a brand new program wherein it’ll match as much as $200 million in donations this yr to a number one basis referred to as Good Days.
The transfer comes after Regeneron a number of months in the past slashed its funding to the charity, an sudden step that appeared largely designed to blunt using eye medicines bought by rivals, however one which has lowered affected person entry and, in flip, sparked concern amongst buyers and physicians.
Certainly, that call has slowed the corporate’s income progress and has prompted some ophthalmologists to complain their sufferers have been shedding entry to wanted remedies. The American Society of Retinal Specialists, for example, issued affected person bulletins and held on-line classes for docs searching for to assist sufferers afford injectable medicines to fight macular degeneration and different eye ailments.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
